Intellia VP sells shares to cover RSU taxes

Intellia Therapeutics, Inc. executive Michael P. Dube, VP and Chief Accounting Officer, reported a sale of 2,641 shares of common stock on July 1, 2026 at a weighted average price of $16.78 per share.

Rhea-AI Filing Summary

Intellia Therapeutics, Inc. executive Michael P. Dube, VP and Chief Accounting Officer, reported a sale of 2,641 shares of common stock on July 1, 2026 at a weighted average price of $16.78 per share.

According to the disclosure, this was a mandatory “sell-to-cover” transaction to satisfy tax withholding obligations triggered by the vesting of restricted stock units (RSUs) on the same date, and is explicitly described as not a voluntary trade. After this tax-related sale, Dube held 66,886 shares of Intellia common stock directly.

Insider Trade Summary

Net Seller: 2,641 shares

Net Sell 1 txn

Insider Dube Michael P

Role VP, Chief Accounting Officer

Sold 2,641 shs ($44K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,641	$16.78	$44K

Holdings After Transaction: Common Stock — 66,886 shares (Direct)

Footnotes (2)

1. F1. Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 1, 2026, and does not represent a volitional trade by the Reporting Person.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.78 to $17.12, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 1, 2026 at each separate price.

Key Figures

Shares sold: 2,641 shares Weighted average sale price: $16.78 per share Shares held after transaction: 66,886 shares +1 more

4 metrics

Shares sold 2,641 shares Mandatory sell-to-cover on July 1, 2026

Weighted average sale price $16.78 per share Open-market sale with prices from $16.78 to $17.12

Shares held after transaction 66,886 shares Direct ownership following July 1, 2026 sale

RSU vesting date July 1, 2026 Triggered tax withholding and sell-to-cover transaction

Key Terms

sell-to-cover, RSUs, weighted average price, open-market sale

4 terms

sell-to-cover financial

"Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation"

Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.

RSUs financial

"tax withholding obligation upon the vesting of RSUs on July 1, 2026"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Intellia Therapeutics (NTLA) report for Michael P. Dube?

Intellia Therapeutics reported that VP and Chief Accounting Officer Michael P. Dube sold 2,641 shares of common stock. The sale occurred on July 1, 2026 and was tied to RSU vesting and related tax withholding obligations, rather than a discretionary open-market trade.

Why did Intellia executive Michael P. Dube sell 2,641 NTLA shares?

The filing states the 2,641-share sale was a mandatory “sell-to-cover” transaction. It was executed to satisfy Dube’s tax withholding obligations arising from the vesting of restricted stock units (RSUs) on July 1, 2026, and is described as not being a volitional trade by him.

At what price were Michael P. Dube’s Intellia (NTLA) shares sold?

The reported sale used a weighted average price of $16.78 per share. A footnote explains the shares were sold in multiple transactions between $16.78 and $17.12 inclusive, and that detailed trade-by-trade pricing information is available upon request from the reporting person.

How many Intellia (NTLA) shares does Michael P. Dube hold after this Form 4 transaction?

After the July 1, 2026 sell-to-cover transaction, Michael P. Dube directly holds 66,886 shares of Intellia Therapeutics common stock. This post-transaction balance is disclosed in the Form 4 and reflects his remaining direct ownership following the 2,641-share tax-related sale.

Was Michael P. Dube’s Intellia (NTLA) share sale a routine tax withholding event?

Yes. The footnote describes the transaction as a mandatory “sell-to-cover” to meet tax withholding on RSU vesting. It emphasizes that the sale does not represent a volitional trade by Dube, indicating it was a routine administrative event linked to equity compensation.

What role does Michael P. Dube hold at Intellia Therapeutics (NTLA)?

Michael P. Dube is identified as an officer of Intellia Therapeutics, serving as Vice President and Chief Accounting Officer. His position is disclosed in the Form 4, which reports his equity transaction and confirms he is not listed as a director or a 10% beneficial owner.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/06/2026 - 05:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dube Michael P

(Last) (First) (Middle)

C/O INTELLIA THERAPEUTICS, INC.

40 ERIE STREET; SUITE 130

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Chief Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		S(1)		2,641	D	$16.78(2)	66,886	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 1, 2026, and does not represent a volitional trade by the Reporting Person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.78 to $17.12, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 1, 2026 at each separate price.

	James Basta, attorney-in-fact	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)